Email updates

Keep up to date with the latest news and content from BMC Neurology and BioMed Central.

Open Access Research article

Specificity of transcranial sonography in parkinson spectrum disorders in comparison to degenerative cognitive syndromes

Kristina Laučkaitė1*, Daiva Rastenytė1, Danguolė Šurkienė1, Antanas Vaitkus1, Andrius Sakalauskas2, Arūnas Lukoševičius2 and Rymantė Gleiznienė3

Author Affiliations

1 Department of Neurology, Lithuanian University of Health Sciences, Academy of Medicine, Mickevičiaus street 9, Kaunas, Lithuania

2 Biomedical Engineering Institute, Kaunas University of Technology, Studentų street 65, Kaunas, Lithuania

3 Department of Radiology, Lithuanian University of Health Sciences, Academy of Medicine, Mickevičiaus street 9, Kaunas, Lithuania

For all author emails, please log on.

BMC Neurology 2012, 12:12  doi:10.1186/1471-2377-12-12

Published: 8 March 2012



Hyperechogenicity of the substantia nigra (SN+), detected by transcranial sonography (TCS), was reported as a characteristic finding in Parkinson's disease (PD), with high diagnostic accuracy values, when compared mainly to healthy controls or essential tremor (ET) group. However, some data is accumulating that the SN + could be detected in other neurodegenerative and even in non-neurodegenerative disorders too. Our aim was to estimate the diagnostic accuracy of TCS, mainly focusing on the specificity point, when applied to a range of the parkinsonian disorders, and comparing to the degenerative cognitive syndromes.


A prospective study was carried out at the Hospital of Lithuanian University of Health Sciences from January until September 2011. Initially, a TCS and clinical examination were performed on 258 patients and 76 controls. The General Electric Voluson 730 Expert ultrasound system was used. There were 12.8% of cases excluded with insufficient temporal bones, and 4.3% excluded with an unclear diagnosis. The studied sample consisted of the groups: PD (n = 71, 33.2%), ET (n = 58, 27.1%), PD and ET (n = 10, 4.7%), atypical parkinsonian syndromes (APS) (n = 3, 1.4%), hereditary neurodegenerative parkinsonism (HDP) (n = 3, 1.4%), secondary parkinsonism (SP) (n = 23, 10.8%), mild cognitive impairment (MCI) (n = 33, 15.4%), dementia (n = 13, 6.1%), and control (n = 71).


There were 80.3% of PD patients at stages 1 & 2 according to Hoehn and Yahr. At the cut-off value of 0.20 cm2 of the SN+, the sensitivity for PD was 94.3% and the specificity - 63.3% (ROC analysis, AUC 0.891), in comparison to the rest of the cohort. At the cut-off value of 0.26 cm2, the sensitivity was 90% and the specificity 82.4%.

The estimations for the lowest specificity for PD, in comparison to the latter subgroups (at the cut-off values of 0.20 cm2 and 0.26 cm2, respectively) were: 0% and 33.3% to APS, 33.3% and 66.7% to HDP, 34.8% and 69.6% to SP, 55.2% and 82.8% to ET, 75% and 91.7% to dementia.


The high sensitivity of the test could be employed as a valuable screening tool. But TCS is more useful as a supplementary diagnostic method, due to the specificity values not being comprehensive.

Transcranial sonography; Substantia nigra; Parkinson's disease; Cognitive disorders; Specificity; Sensitivity